A Phase I Pharmacodynamic Study of Copanlisib (BAY 80-6946) as Monotherapy in Patients With Non-Hodgkin's Lymphoma and Solid Tumors

Trial Profile

A Phase I Pharmacodynamic Study of Copanlisib (BAY 80-6946) as Monotherapy in Patients With Non-Hodgkin's Lymphoma and Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Copanlisib (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Pharmacodynamics
  • Sponsors Bayer
  • Most Recent Events

    • 07 Dec 2017 According to a Bayer media release, data from the study will be presented at the 59th Annual Meeting of the American Society of Hematology (ASH).
    • 10 Jun 2017 Biomarkers information updated
    • 06 Apr 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top